Cost-effectiveness of Emollients in the Prevention of Relapse among French Patients with Atopic Dermatitis
DOI:
https://doi.org/10.2340/00015555-3873Keywords:
dermatitis, atopic, secondary prevention, cost-benefit analysisAbstract
Atopic dermatitis affects up to 20% of children and quite frequently persists in adulthood. Follow-up, treatment, and prevention of relapses have an impact on healthcare spending. The aim of this study was to assess the cost-effectiveness of different emollients prescribed for patients with atopic dermatitis in France. A 3-health state Markov model was designed, using French data for resource utilization, price and transition probabilities. The effects of the use of 5 different emollients (A, B, C, D, E) or no emollient were compared. The selected outcome was time (years) without flare-up (YWFU). The 5-year cost for emollient A is 1,575.64€, and the effectiveness is 3.89 YWFU. Strategy A is the most effective. Compared with treatment E, which was the least expensive emollient, A is more expensive (+481.84€) and more effective (0.082 YWFU). The incremental cost-effectiveness ratio is 5,877.48€/YWFU. In conclusion, treating atopic dermatitis with emollients is a cost-effective strategy.
Downloads
References
Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006; 368: 733–743.
Deckers IAG, McLean S, Linssen S, Mommers M, van Schayck CP, Sheikh A. Investigating international time trends in the incidence and prevalence of atopic eczema 1990–2010: a systematic review of epidemiological studies. Kirk M, editor. PLoS One 2012; 7: e39803.
Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab 2015; 66: 8–16.
Lavery M, Stull C, Kinney M, Yosipovitch G. Nocturnal pruritus: the battle for a peaceful night’s sleep. Int J Mol Sci 2016; 17: 425.
Ma L, Li P, Tang J, Guo Y, Shen C, Chang J, et al. Prolonging time to flare in pediatric atopic dermatitis: a randomized, investigator-blinded, controlled, multicenter clinical study of a ceramide-containing moisturizer. Adv Ther 2017; 34: 2601–2611.
Wirén K, Nohlgård C, Nyberg F, Holm L, Svensson M, Johannesson A, et al. Treatment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial. J Eur Acad Dermatol Venereol 2009; 23: 1267–1272.
van Zuuren EJ, Fedorowicz Z, Christensen R, Lavrijsen AP, Arents BW. Emollients and moisturisers for eczema. Cochrane Skin Group, editor. Cochrane Database Syst Review 2017 Feb 6 [cited 2019 Jan 3]; Available from: http://doi.wiley.com/10.1002/14651858.CD012119.pub2.
National Institute for Health and Care Excellence. The Guidelines Manual: Process and methods. London (GB); 2012 Nov 30. Process and Methods Guides No. 6. PMID: 27905714.
Blank IH. Action of emollient creams and their additives. J Am Med Assoc 1957; 164: 412–415.
Seite S, Bieber T. Barrier function and microbiotic dysbiosis in atopic dermatitis. Clin Cosmet Investig Dermatol 2015; 8: 479–483.
Hjalte F, Asseburg C, Tennvall GR. Cost-effectiveness of a barrier-strengthening moisturizing cream as maintenance therapy vs. no treatment after an initial steroid course in patients with atopic dermatitis in Sweden – with model applications for Denmark, Norway and Finland. J Eur Acad Dermatol Venereol 2010; 24: 474–480.
Hjelmgren J, Svensson A, Jörgensen ET, Lindemalm-Lundstam B, Ragnarson Tennvall G. Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data. Br J Dermatol 2007; 156: 913–921.
Beck R, Pauker SG. Does DEALE-ing stack the deck? Med Decis Making 1999; 503–504.
Seite S, Zelenkova H, Martin R. Clinical efficacy of emollients in atopic dermatitis patients ; relationship with the skin microbiota modification. Clin Cosmet Investig Dermatol 2017; 10: 25–33.
Angelova-Fischer I, Rippke F, Richter D, Filbry A, Arrowitz C, Weber T, et al. Stand-alone emollient treatment reduces flares after discontinuation of topical steroid treatment in atopic dermatitis: a double-blind, randomized, vehicle-controlled, left-right comparison study. Acta Derm Venereol 2018; 98: 517–523.
Tiplica GS, Boralevi F, Konno P, Malinauskiene L, Kaszuba A, Laurens C, et al. The regular use of an emollient improves symptoms of atopic dermatitis in children: a randomized controlled study. J Eur Acad Dermatol Venereol 2018; 32: 1180–1187.
Kim JP, Chao LX, Simpson EL, Silverberg JI. Persistence of atopic dermatitis (AD): a systematic review and meta-analysis. J Am Acad Dermatol 2016; 75: 681–687.e11.
Naimark DMJ, Bott M, Krahn M. The half-cycle correction explained: two alternative pedagogical approaches. Med Decis Making 2008; 28: 706–712.
Haute Autorité de Santé. Choix méthodologique pour l’évaluation économique à la HAS. Paris, France (FR); 2020 Jul. (Guide méthodologique). Available from: https://www.has-sante.fr/upload/docs/application/pdf/2020-07/guide_methodologique_evaluation_economique_has_2020_vf.pdf.
Åkerström U, Reitamo S, Langeland T, Berg M, Rustad L, Korhonen L, et al. Comparison of moisturizing creams for the prevention of atopic dermatitis relapse: a randomized double-blind controlled multicentre clinical trial. Acta Derm Venereol 2015; 95: 587–592.
Haute Autorité de Santé. Commission de la transparence – Avis du 11 juillet 2018 : Dupilumab [Internet]. 2018 May [cited 2019 Dec 17]. Available from: https://www.has-sante.fr/upload/docs/evamed/CT-16605_DUPIXENT_PIC_INS_avis3_CT16605.pdf.
Taieb DC, Association Française Eczéma. Etude sur la dermatite atopique de l’adulte - ECLA: Rapport statistique. 2017 Jul p. 105.
Launois R, Ezzedine K, Cabout E, Reguai Z, Merrhand S, Heas S, et al. Importance of out-of-pocket costs for adult patients with atopic dermatitis in France. J Eur Acad Dermatol Venereol 2019; 33: 1921–1927.
Drummond M, McGuire A, editors. Economic evaluation in health care: merging theory with practice. Oxford: Oxford University Press; 2001, p. 296.
Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ 1998; 7: 723–740.
Terrés CR, Rodríguez DR. Probabilistic analysis: Sensitivity analysis or main result? Pharamcoeconomics. 2016 [cited 2021 Feb 2];01(02). Available from: https://www.omicsonline.org/open-access/probabilistic-analysis-sensitivity-analysis-or-main-result-pe-1000e102.php?aid=72482.
Claxton K. Exploring uncertainty in cost-effectiveness analysis. Pharmacoeconomics. 2008; 26: 781–798.
Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. Value Health 2012; 15: 835–842.
van den Hout WB. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis 2010; 69: i89-91.
Pohar R, McCormack S. Emollient treatments for atopic dermatitis: a review of clinical effectiveness, cost-effectiveness, and guidelines. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 [cited 2021 Feb 18]. (CADTH Rapid Response Reports). Available from: http://www.ncbi.nlm.nih.gov/books/NBK544513/.
Cabout E, Eymere S, Launois R, Aslanian F, Taïeb C, Seité S. Cost effectiveness of emollients in the prevention of relapses in atopic dermatitis. Clin Cosmet Investig Dermatol 2020; 13: 987–996.
Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis. J Am Acad Dermatol 2014; 71: 116–132.
Schonmann Y, Mansfield KE, Hayes JF, Abuabara K, Roberts A, Smeeth L, et al. Atopic eczema in adulthood and risk of depression and anxiety: a population-based cohort study. J Allergy Clin Immunol Pract 2020; 8: 248-257.e16.
Cork MJ, Britton J, Butler L, Young S, Murphy R, Keohane SG. Comparison of parent knowledge, therapy utilization and severity of atopic eczema before and after explanation and demonstration of topical therapies by a specialist dermatology nurse. Br J Dermatol 2003; 149: 582–589.
Moncrieff G, Lied-Lied A, Nelson G, Holy CE, Weinstein R, Wei D, et al. Cost and effectiveness of prescribing emollient therapy for atopic eczema in UK primary care in children and adults: a large retrospective analysis of the Clinical Practice Research Datalink. BMC Dermatol 2018 Oct 29; 18. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206824/.
Ministère des Solidarités et de la Santé. Ma Santé 2022, un engagement collectif. Dossier de Presse [Internet]. Paris, France (FR); 2018 Sep. Available from: https://solidarites-sante.gouv.fr/IMG/pdf/ma_sante_2022_pages_vdef_.pdf.
Additional Files
Published
How to Cite
License
Copyright (c) 2021 Elise Cabout, Sébastien Eymere, Robert Launois, Sophie Séité, Véronique Delvigne, Charles Taïeb, Ziad Reguai
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
